Earlier this month, PPMD joined 129 patient advocacy and provider organizations in a letter to Congress urging them to enact the 2022 Defense Appropriations Act to ensure that the Defense Health Research Programs, including the Congressionally Directed Medical Research Programs (CDMRP), are fully funded in fiscal year 2022. The CDMRP is an important federally-funded research program within the Department of Defense that has been instrumental in advancing early and late state research and drug development tools for Duchenne.
Earlier this year Advocates from around the country spoke with members of Congress during PPMD’s largest advocacy conference marking 20 years of Duchenne advocacy and passage of the MD-CARE Act. Fortunately, thanks to our advocacy, both the House and the Senate have supported Duchenne-specific research funding at the Department of Defense for fiscal year 2022. However, if Congress does not pass the Defense Appropriations bill for FY22, that funding will not come to fruition.
PPMD will continue to advocate on behalf of the community to ensure programs such as these continue to drive innovation and research for the Duchenne community. Thank you to the hundreds of advocates who made their voices heard earlier this year during the 2021 Advocacy Conference.